Free Newsletter
Actos on a good-news roll
The EU's drug committee also gave the go-ahead for a new combo pill that melds the diabetes remedy Actos with old blood-sugar standby metformin. This thumbs-up follows a spate of good news for Actos, including a new study unveiled Wednesday that showed it controlled blood sugar and lipid levels better than Avandia did. Another study, presented at the same meeting of the European Association for the Study of Diabetes, showed that Actos cut heart attack risk by 38 percent.
- check out this EMEA release on the Actos combo drug
- and this release on the Actos studies
Related Articles:
Actos study points to reduction in heart attacks, strokes. Report
Diabetes drug helps reduce rate of strokes. Report
Avandia risks back in the headlines. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: